1
Understanding cancer immunotherapy with genomics Immunotherapies have shown incredible promise as a form of cancer treatment Interest in immunotherapy research has been growing But the data often reveal variability in patient responses Get a complete view of cancer and immune system biology to guide your journey in immuno-oncology research Publications in immunotherapy by year since 2000. 20 % H o w e v e r , th e 2 0 % w ho res po nd ed ex per i e nced a l o n g-t e rm c l i ni c a l b e n e f i t . Today there are over 2,000 open clinical trial sites studying immunotherapy for cancer 600 500 400 300 200 100 0 So how can we determine which therapy will yield a favorable response in a given patient? Clinical studies of exceptional responders…have highlighted NRAS mutation status, total neoantigen load, and a neoantigen-derived tetrapeptide signature as possible correlates of response to ipilimumab in metastatic melanoma. VanAllen et al, 2015 A study of a CTLA4 blockade via the mAb ipilimumab yielded a response rate of only 20%. Discover more with NGS 145 634 24 73 46 238 41 43 87 8 1579 42 26 31 Source: Le at al. N Engl J Med. 2015;372:2509-2520. Source: Thompson Reuters ISI Web of Science (search: immune+cancer+sequencing+clinical from 2000-2016). Source: https://clinicaltrials.gov/ct2/results/map?term=immune+and+cancer&recr=Open&no_unk=Y. Source: Van Allen et al. Science. 2015;350(6257):207-211. *For Research Use Only. Not for use in diagnostic procedures. www.illumina.com/immuno-oncology 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 8 samples 1 gene 24 samples, 1 run Thousands of genes NGS enables a comprehensive assessment of neoantigens and gene expression signatures to identify biomarkers for immunomodulatory therapies. NGS IHC analysis In 2015, one study yielded an objective response rate of 40% in patients with mismatch-repair nt colorectal cancer
